Name
Osaühing FibroTx
Registry code
11183541
VAT number
EE101015402
Type
OÜ - Limited Liability Company
Status
In liquidation
Foundation date
07.11.2005 (19)
Financial year
01.01-31.12
Capital
80 000.00 €
Activity
72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| OÜ Lost Gorillas 16211897 | 3% - 2 400.00 EUR | - | - | |
| AKH Investeeringud OÜ 11934160 | 24% - 19 200.00 EUR | - | - | |
| Osaühing ProtoBioS 10981915 | 18% - 14 400.00 EUR | - | - | Founder |
| Aifal OÜ 12411530 | 17% - 13 991.00 EUR | - | - | |
| OÜ Kähri & Kaarin 11208488 | 13% - 10 209.00 EUR | - | - | |
| Omanikukonto: AIVAR LINNAMÄE 02.04.1962 (62) | - | Liquidator | Indirect ownership |
| 2019 14.09.2020 | 2020 30.06.2021 | 2021 07.07.2022 | 2022 27.06.2023 | |
|---|---|---|---|---|
| Total Revenue | 237 871 € | 164 291 € | 221 916 € | 52 978 € |
| Net profit (loss) for the period | -1 419 011 € | -1 131 487 € | -1 573 505 € | -5 006 232 € |
| Profit Margin | -597% | -689% | -709% | -9450% |
| Current Assets | 202 438 € | 47 010 € | 166 092 € | 607 € |
| Fixed Assets | 1 271 862 € | 1 515 584 € | 2 067 567 € | 0 € |
| Total Assets | 1 474 300 € | 1 562 594 € | 2 233 659 € | 607 € |
| Current Liabilities | 421 123 € | 691 274 € | 1 160 844 € | 10 314 350 € |
| Non Current Liabilities | 3 655 696 € | 4 605 326 € | 6 380 326 € | 0 € |
| Total Liabilities | 4 076 819 € | 5 296 600 € | 7 541 170 € | - |
| Share Capital | - | - | - | - |
| Equity | -2 602 519 € | -3 734 006 € | -5 307 511 € | -10 313 743 € |
| Employees | 14 | 9 | 9 | 7 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | - | - | - | - |
| 2023 Q4 | - | - | 32.27 € | - |
| 2023 Q3 | - | - | - | - |
| 2023 Q2 | - | - | - | - |
| 2023 Q1 | 2 759.92 € | 17 627.14 € | 31 723.2 € | - |
| 2022 Q4 | 27 718.37 € | - | 51 619.09 € | 9 |
| 2022 Q3 | 57 273.09 € | - | 28 279.32 € | 16 |
| 2022 Q2 | 26 751.71 € | - | 35 851.35 € | 17 |
| 2022 Q1 | 118 363.73 € | 12 548.62 € | 34 129.31 € | 20 |
| 2021 Q4 | 116 936.43 € | - | 33 999.48 € | 20 |
| 2021 Q3 | 124 489.39 € | 11 850.85 € | 27 784.96 € | 20 |
| 2021 Q2 | 67 562.28 € | - | 25 928.88 € | 19 |
| 2021 Q1 | 144 572.18 € | - | 23 789.4 € | 17 |
| 2020 Q4 | 75 378.41 € | - | 23 587.64 € | 17 |
| 2020 Q3 | 38 534.89 € | 24 628.61 € | 26 493.84 € | 16 |
| 2020 Q2 | 223 260.25 € | 43 603.99 € | 46 737.83 € | 18 |
| 2020 Q1 | 74 258.41 € | 38 711.75 € | 40 611.81 € | 23 |
